<!DOCTYPE HTML>
<html lang="es">

<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>

<body>

	<div class='preloader'>
		<div class='loaded'>&nbsp;</div>
	</div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
						<nav class="navbar navbar-default">
							<div class="container-fluid">
								<!-- Brand and toggle get grouped for better mobile display -->
								<div class="navbar-header">
									<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
									</button>
									<a class="navbar-brand" href="index.html">
										<div class="logo">
											<img src="images/vikhiLOGOsm.png" alt="" height="30">
										</div>
									</a>
								</div>

								<!-- Collect the nav links, forms, and other content for toggling -->
								<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

									<ul class="nav navbar-nav navbar-right">
										<li><p><a href="index.html#index">ÍNDICE</a><br><a href="index.html#index"><span class="gris">INDEX</span></a></p></li>

									</ul>
								</div><!-- /.navbar-collapse -->
							</div><!-- /.container-fluid -->
						</nav>
					</div>
				</div>
				<!--Fin de row -->

			</div>
			<!--Fin de container -->

		</div>
	</header>
	<!--Fin de header -->

	<section>
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="parrafo text-center wow fadeIn" data-wow-duration="1.5s">
							<div class="video">
							<iframe src="https://www.youtube.com/embed/N2kivQioq7k?rel=0" frameborder="0" allowfullscreen="allowfullscreen"></iframe>
							</div>
							<div class="title_text">
								<br>
								<br>
								<h1><span class="negrita">5</span></h1>
								<br>
								<h6>Toxicidad Digestiva y Renal</h6>
								<h6><span class="gris">&nbsp&nbsp&nbspGastrointestinal and Kidney Toxicity</span></h6>
							</div>
							<div class="single_right_text">
								<br>
								<br>
								<table class="vikhi-tablalink">
									<col width="20%">
									<col width="80%">
									<tr>
										<td><p>Silvia Salord</p></td>
										<td>
											<p><span class="negrita">/</span> Servicio de Gastroenterología, Hospital Universitario de Bellvitge</p>
										</td>
									</tr>
									<tr>
										<td><p></p></td>
										<td>
											<p><span class="gris">&nbsp&nbsp&nbspGastroenterology Department, Bellvitge University Hospital</span></p>
										</td>
									</tr>
									<tr>
										<td><p>Juliana Bordignon</p></td>
										<td>
											<p><span class="negrita">/</span> Servicio de Nefrología, Hospital Universitario de Bellvitge</p>
										</td>
									</tr>
									<tr>
										<td><p></p></td>
										<td>
											<p><span class="gris">&nbsp&nbsp&nbspNephrology Department, Bellvitge University Hospital</span></p>
										</td>
									</tr>
								</table>
							</div>



							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<p>Descarga los archivos relacionados con este video haciendo click en los siguientes enlaces:</p>
									<p><span class="gris">Download the articles on the subject by clicking on the links below:</span></p>
									<br>
									<table class="vikhi-tablalink">
										<tr>
											<td><a href=docs/silviaSalord.pdf download><img src="images/download.png" alt="" height="20px"></a></td>
											<td>
												<p><a href=docs/silviaSalord.pdf download>Digestive toxicity</a></p>
											</td>
										</tr>
										<tr>
											<td><a href=docs/julianaBordignon.pdf download><img src="images/download.png" alt="" height="20px"></a></td>
											<td>
												<p><a href=docs/julianaBordignon.pdf download>Renal effects of immune checkpoint inhibitors</a></p>
											</td>
										</tr>

									</table>
								</div>
							</div>

							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>DIGESTIVE TOXICITY</h4>
									<br>
									<p>Silvia Salord <span class="negrita">/</span> Gastroenterology Department, Bellvitge University Hospital</p>
									<br>
									<p>The incidence of diarrhoea among patients treated with anti-CTLA4 is 27-54%, while
the incidence of colitis ranges from 8-22%. Bowel perforation is reported in 1% of cases
(ipilimumab).</p>
									<br>
									<p>Liquid diarrhoea is the principal symptom and it may be accompanied by abdominal
pain, haematochezia and fever (which are indicators of greater severity). Diarrhoea and/
or colitis may occur months after the end of treatment with immunotherapy and may
mimic inflammatory bowel disease.
									</p>
									<br>
									<p>The clinical condition can be categorised as grade 1 ( < 4 liquid stools/day, good general
condition), grade 2 (4-6 liquid stools/day, or abdominal pain or haematochezia or
nausea or nocturnal episodes, without affecting the patient’s general condition), grade
3 (>7 liquid stools/day, incontinence, affecting the patient’s general condition, requires
hospitalisation) or grade 4 (life-threatening severity, urgent intervention indicated),
depending on the severity.</p>
									<br>
									<p>There are no prophylactic treatments for immune-mediated colitis.</p>
									<br>
									<p>From grade 2 and above, it is advisable to perform a complete blood panel (blood count,
clinical chemistry, TSH, CRP and ESR), as well as a stool analysis (stool culture, Clostridium
toxin, parasites, etc.). On the other hand, in more serious cases, it is recommended
to perform the screening prior to the administration of an anti-TNF (viral serologies,
HIV, QuantiFERON, etc.). The role of faecal calprotectin in this patient profile is not well
established, although it would seem that it may help to suspect an inflammatory cause
and during follow-up.</p>
									<br>
									<p>Proctosigmoidoscopy/colonoscopy is recommended for persistent grade 2 toxicity
and for grade 3/4. The findings may range from a normal colonic mucosa to exudates,
granularity, loss of vascular pattern and ulcerations.</p>
									<br>
									<p>Regarding treatment, in grade 1, symptomatic treatment, astringent (anti-diarrhoea)
diet, hydration and anti-diarrhoeal drugs are recommended. In grade 2, treatment with
immunotherapy should be suspended and oral corticosteroids started, while in grades
3-4, treatment with IV corticosteroids (1-2 mg/kg/day) is recommended, and if there is
2
no response on the 3rd day, treatment with infliximab should be started. Cases have
been reported that have responded to treatment with vedolizumab.</p>
								</div>
							</div>
							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>HEPATOTOXICITY</h4>
									<br>
									<p>Silvia Salord <span class="negrita">/</span> Gastroenterology Department, Bellvitge University Hospital</p>
									<br>
									<p>The incidence of hepatitis as an adverse effect of immunotherapy is 5-10% (1-2% of
which is grade 3) in patients treated with ipilimumab, nivolumab and pembrolizumab
in monotherapy, while this rises to 25-30% in those patients treated with two drugs in
combination (ipilimumab and nivolumab).</p>
									<br>
									<p>It is recommended that all patients who are going to receive treatment with immunotherapy
should undergo baseline lab tests with liver function tests (transaminases, bilirubin,
albumin, etc.) and viral serology testing (HBV, HCV and HIV), repeating the determination
of transaminases and bilirubin prior to each cycle.
									</p>
									<br>
									<p>In most cases when hepatitis is diagnosed, the patient is asymptomatic and the
elevation of transaminases is detected in the routine check-up (but jaundice, fatigue,
etc. may also be detected). A differential diagnosis is very important in the event of
elevated transaminase levels. A thorough anamnesis should be performed to ascertain
the existence of concomitant symptoms (fever, abdominal pain, jaundice, pruritus, etc.),
all the drugs that the patient has received, if he/she has taken herbal products, if he/she
consumes alcohol or other drugs, etc.</p>
									<br>
									<p>Depending on the transaminase levels, hepatitis will be classified as grade 1 (ALT or
AST>ULN-3xULN), grade 2 (ALT or AST 3-5x ULN), grade 3 (ALT or AST 5-20x ULN) or
grade 4 (ALT or AST> 20x ULN).</p>
	<br>
	<p>For grade 1 hepatitis, treatment with immunotherapy can be continued and the lab tests
can be repeated after one week.</p>
									<br>
									<p>In grade 2 hepatitis, it is advisable to delay treatment and repeat the lab tests with
liver function tests every 3 days, as well as to repeat viral serologies (HAV, HBV, HCV,
HEV), autoimmune hepatitis autoantibodies, ferritin, TSH, and to assess a liver imaging
test (ruling out metastasis, vascular thrombosis, etc.). If the results are negative and
elevated transaminase levels persist, or there is grade 3/4 of toxicity, it is advisable to
start treatment with corticosteroids (1-2mg/kg/day). If, after three days of treatment
with intravenous corticosteroids there is no improvement, it is recommended to start
mycophenolate.</p>
									<br>
									<p>A liver biopsy should be considered in cases of severe hepatitis, for differential diagnosis
(the most common finding is lobular hepatitis indistinguishable from autoimmune
hepatitis).</p>
								</div>
							</div>
							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>RENAL EFFECTS OF IMMUNE CHECKPOINT INHIBITORS</h4>
									<br>
									<p>Juliana Bordignon <span class="negrita">/</span> Nephrology Department, Bellvitge University Hospital</p>
									<br>
									<h6>Introduction</h6>
									<br>
									<p>The immune system plays a critical role in the control and eradication of cancer cells.
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1)
are two important immune checkpoint; their ligands are CD80/CD86 B7 and programmed
cell death ligand 1 (PD-L1), respectively. Following binding of the receptors to their
specific ligands, T-cell effectors are downregulated, leading to tumor cell tolerance. On
the other hand, the inhibition of these immune checkpoint proteins reestablishes the
response of T lymphocytes against cancer cells.</p>
<br>
<p>Monoclonal antibodies against PD1 (nivolumab, pembrolizumab), PDL-1(atezolizumab)
and CTLA-4(ipilimumab) are currently being used for treatment of advanced stage
cancers with unprecedented results in survival data. However, recent studies have
shown that Checkpoint Inhibitors (CI)-based combinations caused an increased
risk of immune-related adverse events (AEs), such as liver, gastrointestinal, skin and
pulmonary toxicities. Other rare AEs that have been reported include uveitis, pancreatitis,
neuropathies, pneumonitis, myocarditis and renal disorders. Despite being relatively
rare (≤1%), the renal affectation should be emphasized because the prognosis of cancer
patients with kidney dysfunction has been previously shown to be poor. Moreover, the
incidence of renal related adverse events seems to increase until 5% on CI combined
therapy.</p>
<br>
<h6>Immune-related renal effects of Checkpoint Inhibitors</h6>
<br>
<p>Two different forms of CI-induced renal diseases have been reported in the literature: acute
tubulointerstitial nephritis (AIN) and some cases of immune complex glomerulonephritis.</p>
<br>
<p>Acute interstitial nephritis induced by CIs is related to severe inflammatory cell infiltrates.
In this line, Cortazar described 13 patients with CI-induced acute kidney injury (AKI). The
median time for AKI is variable (21–245 days). Most patients presented with pyuria
(8 patients) low-grade proteinuria (median 0.48 g/g; 0.12–0.98 g/g) and median peak
serum creatinine of 4.5 mg/dL (3.6–7.3 mg/dL). AIN was observed in 12 patients and
glucocorticoid treatment of 10 patients resulted in a complete (2 patients) or partial
2
(7 patients) recovery of renal function. Four patients required haemodialysis despite
treatment with glucocorticoids, of whom only two required chronic dialysis. No
improvement in renal function was seen in the remaining two patients with AIN, who did
not receive glucocorticoid treatment.</p>
<br>
<p>It is believed that cell-mediated immunity is implicated in the mechanism of renal injury.
CI may reactivate exhausted drug-specific T cells previously primed by nephritogenic
drugs, and consequently, due to loss of tolerance, memory T cells are activated against
the drug. In this line, 14 out of the 19 patients reported by Cortazar and Shirali were on
drugs associated with AIN (proton pump inhibitors and non-steroidal anti-inflammatory
drugs).</p>
<br>
<p>Regarding immune –complex glomerulonephritis, one patient was reported with
nephrotic syndrome and preserved renal function on treatment with ipilimumab (for
melanoma). A renal biopsy revealed lupus-related membranous nephropathy with
circulating anti-doublestranded DNA antibodies and glomerular IgG, C3 and C1q
deposits. In another report, kidney biopsy revealed IgA nephropathy in a patient who
developed proteinuria and a worsening kidney function after treatment with nivolumab
for a postoperative recurrence of lung squamous cell carcinoma. After drug withdrawal,
proteinuria improved and the deterioration of the patient’s
renal function was halted.</p>
<br>
<h6>Treatment</h6>
<br>
<p>The current standard of care for drug-induced AIN management includes early
identification of this disease (renal biopsy) and prompt discontinuation of the culprit
medication. Given the underlying immune mediated damage in this disease, steroids
therapy has also been used since 1970. However, there is a lack of high-quality evidence
to support this practice. Despite this deficiency, the available evidence supports a
potential benefit of early steroid administration on long-term recovery of kidney function.</p>
<br>
<p>In relation to check point inhibitors, American and European Oncology guidelines stratifiy
patients managements based in the severity of renal dysfunction. In mild dysfunction
(grade 1) the physician can continue the treatment under strict monitoring of creatinine
values, while promoting hydration and cessation of nephrotoxic drugs. If the renal
function has worsened to grade 2–3 renal toxicity, treatment should be postponed until
creatinine values decrease to at least grade 1, and a renal biopsy should be performed.
Prednisolone 0.5–1 mg/ kg daily should be given. If the renal function has worsened
to grade 4 renal toxicity, treatment must be stopped, a renal biopsy performed and
methylprednisolone dosed at 1–2 mg/kg daily should be given. Moreover, avoidance or
discontinuation of other drugs, those known to induce AIN, should be considered.</p>
								</div>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>





	<section>
		<div class="container">
			<div class="row">
				<div class="parrafo text-center wow fadeIn" data-wow-duration="1.5s">
					<div class="col-sm-12 ">

						<div class="col-md-6 col-sm-6 col-xs-12">
							<h3>ÍNDICE</h3>
						</div>

						<div class="col-md-6 col-sm-6 col-xs-12">
							<h3><span class="gris">INDEX</span></h3>
						</div>
					</div>

				</div>
			<div class="col-sm-12">
					<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video01.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">1</span></h1>
						</div>
						<div class="single_right_text">
							<h4>La revolución de la inmunoterapia en cáncer</h4>

						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
				<a href="video01.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
					<div class="single_left_icon">
						<h1><span class="transparente negrita">1</span></h1>
					</div>
					<div class="single_right_text">

						<h4><span class="gris">The revolution of immunotherapy in cancer</h4>
					</div>
				</div></a>
			</div>
		</div>

		<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video02.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">2</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Manejo del oncólogo médico de la toxicidad</h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video02.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">2</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Management by the medical oncologist of toxicity</h4>
						</div>
					</div></a>
				</div>
			</div>

			<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video03.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">3</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Manejo del paciente en tratamiento con inmunoterapia</h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video03.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">3</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Management of the patient treated with immunotherapy</h4>
						</div>
					</div></a>
				</div>
			</div>

			<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video04.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">4</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Toxicidad cutánea, endocrinológica y pulmonar</h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video04.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">4</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Skin, endocrinological and lung toxicity</h4>
						</div>
					</div></a>
				</div>
			</div>

			<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video05.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">5</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Toxicidad digestiva y renal</h4>
							<h4><br></h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video05.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">5</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Gastrointestinal and kidney toxicity</h4>
						</div>
					</div></a>
				</div>
			</div>

			<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video06.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">6</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Toxicidad neurológica, cardiológica y osteomuscular</h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video06.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">6</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Neurological, cardiological and musculoskeletal toxicity</h4>
						</div>
					</div></a>
				</div>
			</div>

			<div class="col-sm-12">
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video07.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="negrita">7</span></h1>
						</div>
						<div class="single_right_text">
							<h4>Conclusiones</h4>
							<h4><br></h4>
						</div>
					</div></a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video07.html"><div class="contorno wow fadeIn" data-wow-duration="1s">
						<div class="single_left_icon">
							<h1><span class="transparente negrita">7</span></h1>
						</div>
						<div class="single_right_text">
							<h4><span class="gris">Conclusions</h4>
								<h4><br></h4>
						</div>
					</div></a>
				</div>
			</div>

		</div>
	</div>
</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>





	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>

</html>
